July 29, 2026

Diabetes Tied to Hearing Impairment

Researchers found clinically significant hearing loss affected about one in four adults with diabetes and identified stronger associations in studies in the younger-than-60-years subgroup.

Conexiant

July 29, 2026

Can Statin Muscle Risk Be Predicted?

Researchers developed and externally validated a prediction model estimating 1-, 5-, and 10-year risks of serious muscle disorders among patients potentially eligible for statin therapy.

Conexiant

July 29, 2026

Trump Has Quietly Throttled an Agency Devoted to the Safety of American Healthcare

“My salary is gone. The salaries of all my research assistants, survey scientists, all lost. It’s terrible."

Kff Health News

July 23, 2026

New Data for Acquired Hypothalamic Obesity

Researchers found greater reductions in body mass index and participant-reported hunger scores with setmelanotide than with placebo, although adverse and serious adverse events were more frequent in the setmelanotide group; only one serious adverse event was considered treatment-related.

Conexiant

July 23, 2026

Exonate Taps Olav Hellebø as EXN407 Nears Phase 2b

Exonate brings in Olav Hellebø as it prepares Phase 2b trial of EXN407 for diabetic eye disease

The Ophthalmologist

July 22, 2026

Trump’s Personnel Agency Says It Will Remove Some Identifying Info as It Sweeps Up Medical Records

“Clearly, this administration has not earned our trust with Americans’ sensitive data."

Conexiant

July 20, 2026

Can Endotoxin-Targeted Care Improve Sepsis Outcomes?

Biomarker-guided patient selection may help identify patients with sepsis who could benefit from endotoxin-targeted therapy, although confirmatory evidence is still needed.

Conexiant

July 20, 2026

This Week’s CGT News: First-in-Human Diabetes Cell Therapy 

First-in-human diabetes cell replacement, early iPSC-derived CAR T data in systemic sclerosis, AAV gene therapy for fragile X syndrome, and fresh funding for off-the-shelf CAR T

The Medicine Maker

July 20, 2026

Can Patients Switch to Biosimilar Aflibercept?

A 20-week INSIGHT extension suggests that switching from reference aflibercept to MYL-1701P maintained comparable safety, visual, and anatomic outcomes in patients with diabetic macular edema.

Conexiant

July 20, 2026

Mutant KRAS Vaccine for Prevention of Pancreatic Cancer Development Shows Durable Immune Responses

A vaccine targeting common KRAS mutations was safe and stimulated KRAS-specific T-cell responses in 90% of study participants who were at high risk of developing pancreatic ductal adenocarcinoma, acco...

The ASCO Post